Generic Medicine Info
Indications and Dosage
Ocular hypertension, Open-angle glaucoma
Adult: As 0.0015% soln: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, preferably in the evening.
Special Precautions
Patient w/ active intraocular inflammation (e.g. uveitis, iritis), aphakia, pseudoaphakia w/ torn posterior lens capsule, risk factors for cystoid macular oedema, history of herpetic keratitis, severe asthma. Pregnancy and lactation.
Adverse Reactions
Significant: Macular oedema, pigmentation of the iris, eyelid, and eyelashes; eyelash changes.
Nervous: Headache.
Resp: Cough, common cold, asthma exacerbation, dyspnoea.
Genitourinary: UTI.
Ophthalmologic: Conjunctival hyperaemia, allergic conjunctivitis, blurred vision, blepharitis, punctate keratitis, eyelid and conjunctival oedema, dry eye, iritis, uveitis, cataract, ocular pain, eye irritation (e.g. stinging, grittiness, itching), reactivation of herpetic keratitis.
Patient Counseling Information
This drug may cause transient blurring of vision upon instillation, wait until vision clears before driving or operating machinery. May change the colour of the iris, eyelid, and eyelashes; may also cause thickening and lengthening of the eyelashes. Avoid contact w/ skin as it may lead to hair growth or skin pigmentation.
Monitoring Parameters
Monitor IOP. Regularly examine patients who develop increased iris pigmentation.
Drug Interactions
Paradoxical increase in IOP may occur when used w/ other ocular prostaglandin analogues.
Mechanism of Action: Tafluprost is a prodrug of tafluprost acid, a fluorinated prostaglandin F analogue. The exact mechanism by which it reduces intraocular pressure (IOP) is unknown, but is believed to act by increasing the uveoscleral outflow of aqueous humour.
Onset: Reduction of IOP: 2-4 hr.
Duration: ≥24 hr.
Absorption: Absorbed through the cornea. Time to peak plasma concentration: Approx 10 min.
Metabolism: Metabolised via hydrolysis to the biologically active metabolite, tafluprost acid, which is metabolised further via fatty acid β-oxidation and phase II conjugation.
Excretion: Via urine (approx 27-38%) and faeces (approx 44-58%).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tafluprost, CID=9868491, https://pubchem.ncbi.nlm.nih.gov/compound/Tafluprost (accessed on Jan. 23, 2020)

Store between 2-8°C. 
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EE05 - tafluprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Anon. Tafluprost. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/05/2017 .

Buckingham R (ed). Tafluprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/05/2017 .

Joint Formulary Committee. Tafluprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/05/2017 .

McEvoy GK, Snow EK, Miller J et al (eds). Tafluprost (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/05/2017 .

Zioptan Solution/Drops (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/05/2017 .

Disclaimer: This information is independently developed by MIMS based on Tafluprost from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in